IFRS 16 effect on Recipharm's income statement and balance sheet 2019
The new accounting standard, IFRS 16 will have an estimated positive impact on EBITDA of SEK 90 million in 2019. The new accounting standard led to an increase of the opening balance of the financial net debt of SEK 312 million per first of January 2019. More details will be provided in the 2018 Annual Report and in the Q1 2019 interim report.
Thomas Eldered, CEO, telephone: +46 8 602 52 10
Tobias Hägglöv, CFO, email@example.com, +46 8 602 52 00
This information is information that Recipharm AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 12 April 2019, at 14:00 CET.
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm’s turnover is approximately SEK 6.4 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com